EnvoyAI Partner:


Logo_icometrix.png
if_290_279051.png
Year Founded: 2011
if_search_244366.png
Area of Focus/Speciality: Brain with focus on Multiple Sclerosis, dementia and traumatic brain injury
if_hospital_clinic_133105.png
Hospital Associations: University hospitals of Leuven, Belgium and Antwerp, Belgium.
if__location_1964213.png

Reference Sites:

  • Shields
  • Mount Sinai
  • Stanford
  • RadNet
  • CDI
  • Dent Neurological Institute
  • South Shore Neurological Associates
  • Pro Diagnostic Imaging
if__location_1964213.png
Company Headquarters: Leuven, Belgium
2538894-128.png
Number of Machines: 1
icometrix linkedin page
icometrix twitter profile
icometrix facebook page

icometrix

About icometrix

Our mission is to become the standard in biomedical image analysis, starting with the brain.

icometrix provides clinicians with standardized measurements on their patients’ brain MRI scans in order to improve personalized care of people with a neurological disorder.

icometrix was founded in 2011 by Dirk Loeckx and Wim Van Hecke. It is a spin-off company of the universities and university hospitals of Leuven and Antwerp. Today, icometrix has grown to a team of over 25 people and is internationally active, with headquarters in Leuven and an office in Boston, Massachusetts. They are the worldwide standard in MRI biomarkers in routine clinical practice.

icometrix developed MSmetrix, which detects brain lesions, calculates lesion volume and measures the whole brain and grey matter volume and atrophy. MSmetrix received market approval in the EU and other countries including Canada, Brazil and Australia. (The clinical report for the US market is named icobrain, for which icometrix has received 510(k) clearance from the FDA.) Furthermore, icometrix is ISO9001 and ISO13485 (Medical Devices) and ISO27001 (Information Security) certified.

icometrix also acts as an image analysis expert in clinical trials and research studies. Imaging biomarkers constantly lead to new insights on neurological disorders. Since recently, imaging biomarker outcomes often serve as the primary endpoints in clinical trials for the development of new drugs. For these purposes large batches of brain imaging data are frequently transferred to icometrix for fast and high quality processing. This way our software-as-a-service is incorporated in clinical trials and large research studies regarding Traumatic Brain Injury (TBI), Epilepsy, Alzheimer’s Disease, Stroke, etc.

if_newspaper_193067.png
Publications and Press: 
  • Jain S., Sima D., Ribbens A., Cambron M., Maertens A., Van Hecke W., Vrenken H., De Mey J., Maes F., Van Huffel S., Barkhof F., Smeets D., Automatic segmentation and volumetry of multiple sclerosis brain lesions from MR images, NeuroImage Clinical 2015.
  • Jain S., Ribbens A., Sima D., Cambron M., De Keyser J., Wang C., Barnett M., Van Huffel S., Maes F., Smeets D., Two Time Point MS Lesion Segmentation in Brain MRI: An Expectation-Maximization Framework, Frontiers in Neuroscience: Brain Imaging Methods.
  • Smeets D., Ribbens A., Sima D., Cambron M., Horakova D., Jain S., Maertens A., Van Vlierberghe E., Popescu V., Terzopoulos V., Van Binst A., Vaneckova M., Krasensky J., Uher T., Seidl Z., De Keyser J., Nagels G., De Mey J., Havrdova E., Van Hecke W., Reliable measurements of brain atrophy in individual patients with Multiple Sclerosis, Brain and Behavior 2016.
  • Van Schependom J., Jain S., Cambron M. Vanbinst A., De Mey J., Smeets D., Nagels G., Reliability of measuring regional callosal atrophy in neurodegenerative diseases, NeuroImage Clinical 2016.

End-User Testimonials

Testimonial

“The development of brain MRI biomarkers has brought irretrievable changes to the way we interpret imaging studies. Biomarkers provide measurable information about the disease, improve the quality of the report with objective information, facilitate comparison with previous studies, and reduce the time needed for reporting."

Prof. Paul M. Parizel

icometrix Leadership
Wim Van Hecke, PhD CEO

Wim Van Hecke, PhD

CEO

Dirk Smeets, PhD VP Clinical Applications

Dirk Smeets, PhD

VP Clinical Applications

Jan Verheyden VP Traumatic Brain Injury

Jan Verheyden

VP Traumatic Brain Injury

Annemie Ribbens, PhD VP Clinical Trials

Annemie Ribbens, PhD

VP Clinical Trials

Michiel Roels CFO

Michiel Roels

CFO

icometrix Machines | icobrain

icometrix is directly responsible for product and clinical representations

  • MRI brain (T1 weighted and FLAIR)
  • MRI brain (T1 weighted and FLAIR)
  • Icometrix (1).png

icobrain is an FDA-cleared brain MRI tool and is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of MR images. The software is intended to automate the current manual process of identifying, labeling and quantifying the volume of segmentable brain structures identified on MR images.

  • Applicable Study Types: MRI brain (T1 weighted and FLAIR)
  • Regulatory Status: FDA cleared